The National Institutes of Health (NIH) defines a Clinical Trial as a research study in which one or more human subjects are prospectively assigned to one or more interventions. Clinical trials help develop novel drugs (Investigational Products) by providing early access to patients who volunteer to participate in the research study.
Carolina BioOncology Institute and our expert Providers participate in the national clinical trials listed below. The eligibility criteria enables patients with advanced solid tumors to access these Investigational Products. Over the past 15 years, our Clinic has opened over 100 Oncology clinical trials and our experienced staff are happy to discuss options for determining trial eligibility Please view the list of trials below that are currently enrolling patients:
Abbvie M20-124
A Phase 1, Multi-center, Open Label First-in-Human Study with ABBV-CLS-579 Alone and in Combination with aPD-1 in Subjects with Locally Advanced or Metastatic Tumors.
AbbVie M20-431
A Phase 1 Study with ABBV-CLS-484 Alone and in Combination in Subjects with Locally Advanced or Metastatic Tumors.
Abbvie M21-404
A Phase 1 first in human study evaluating safety, pharmacokinetics and efficacy of ABBV-400 in adult subjects with advanced solid tumors.
AbbVie M21-410
A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors with ABBV-514 as a Single Agent and in Combination with Pembrolizumab or Budigalimab.
Allarity Therapeutics APV-527-101
A Study to Determine the Maximum Tolerated Dose of PARPi-2x-121 Monotherapy and the MTD of Dovitinib in Combination with 2x-121 in Patients with Advanced Solid Tumors.
Aptevo Therapeutics APV-527-101
A First-in-human, Multicenter, Open-label, Dose Escalation and Dose Expansion Phase 1 Study in Patients with Advanced Solid Tumors to Evaluate the Safety of Intravenously Administered ALG.APV-527.
Clinicaltrials.gov link still pending
Ascendis ASCEN0029
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination with Pembrolizumab or Chemotherapy in Participants Aged 18 Years or Older with Locally Advanced or Metastatic Solid Tumor Malignancies.
Bristol – Myers Squibb CA111-001
Phase 1 Study of BMS-986406 as Monotherapy and in Combination in Advanced Tumors.
Bristol – Myers Squibb CA115-001
A Study of BMS-986442 With Nivolumb or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer.
Bristol – Myers Squibb IM043004
A Study of BMS-8986360/CC-900001 Alone and in Combination with Chemotherapy or Nivolumab in Advanced Solid Tumors.
Conjupro CPO-100-US-101
A Phase 1, Multi-Center, Single Agent Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of CPO-100 in Adult Patients with Advanced Solid Tumors.
CUE Biopharma CUE-102-01
A Phase I Study in Patients with HLA-A*0201 + and WT1 + Recurrent/Metastatic Cancers.
Cullinan CLN-619-001
A Phase 1 Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors.
GI Innovation GII-101-P101
GI-101 as Single Agent or in Combination with Pembrolizumab, Levantinib or Local Radiotherapy in Advanced Solid Tumors.
Harbor BioMed HBM7008.1
A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of HBM7008in Subjects with Advanced Solid Tumors.
IGM BioSciences IGM7354-001
Evaluation of IGM-7354 in Adults with Relapsed and/or Refractory Solid Tumors.
I-Mab TJ033721STM101
Phase 1 study of TJ033721 in subjects with advanced or metastatic solid tumors.
Immune-Onc IO-108-CL-001
A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of IO-108 as Monotherapy and in Combination With Pembrolizumab, in Adult Subjects With Advanced Relapsed or Refractory Solid Tumors.
Immune-Onc IO-202-CL-002
A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study of IO-202 in Combination with Pembrolizumab in Subjects with Advanced, Relapsed, or Refractory Solid Tumors.
InCyte INCA 0186-101
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors.
InCyte INCAGN 2385-201
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti–PD-1), INCAGN02385 (Anti–LAG-3), and INCAGN02390 (Anti–TIM-3) in participants with Select Advanced Malignancies.
InCyte INCB 123667-101
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors.
Jounce JTX 8064-101
Phase 1 First-in-Human Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX 8064, as Monotherapy and in Combination with a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects with Advanced Refractory Solid Tumor Malignancies.
Macrogenics CP-MGC018-02
A Phase 1/1b Dose Escalation and Cohort Expansion Study of MGC018 in Combination with MGD019 in Participants with Advanced Solid Tumors.
Clinicaltrials.gov link still pending
Medikine MDK-703-102
A Dose Escalation/Expansion Study of MDK-703 in Patients with Advanced or Metastatic Solid Tumors.
Moderna mRNA-4359-P101
A Study of mRNA-4359 Administered Aline and in Combination with Immune Checkpoint Blockade in Participants with Advanced Solid Tumors.
Nuvation NUV-868-01
Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors.
PEEL Therapeutics PEEL-224-001
An Early Phase Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Preliminary Antitumor Activity of PEEL-224 in Patients with Advanced Solid Tumors.
Phanes PT199X1101
A Dose Escalation/Expansion Study of PT199 (an Anti-CD73 mAb) Administered Alone and in Combination with a PD-1 Inhibitor.
Pieris CL1-95012-001
A Study of PRS-344-S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients with Solid Tumors.
Riboscience RBS2418
An Evaluation of RBS2418 in Subjects with Unresectable or Metastatic Tumors.
Simcere SIM1811-03
A Phase I Trial of SIM1811-03 in Subjects with Advanced Solid Tumors and Cutaneous Lymphoma.
SK Life Science SK27969C001
Safety, Tolerability, PK/PD and Preliminary Efficacy of SKL27969 in Advanced Solid Tumor Patients (Including Glioblastoma Multiforme).
Trethera TRE515-T-02
A Phase 1, Open-Label, First-In-Human, Dose-Escalation Study with Expansion to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered TRE-515 in Subjects with Solid Tumors.
Xilio XTX202-01/02-001
A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX101 in Patients with Advanced Solid Tumors.
Zenshine ZX-4081-101
A Phase 1, Open-Label, First in Human, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZX-4081 in Patients with Advanced Solid Tumors.